AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 171 min read$INCY

CAGNONI PABLO J sold $2.8M of INCY

CAGNONI PABLO J (President, Global Head of R&D) sold 23,218 shares of INCYTE CORP (INCY) at an average of $120.49 ($120.49–$120.50, $2.80M total) across 2 trades on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CAGNONI PABLO J
Published Sep 17, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$INCY
Neutral
medium confidence
Mentioned
$INCY
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INCYNeutralLow
01

Why it matters

Provides transparency but limited trading relevance for the stock.

02

Market read

Minor insider sale with modest dollar value; unlikely to move the market.

03

What to watch

Potential upcoming R&D milestones not disclosed.

Relevance 5/10Novelty 4/10Timing: filed Sep 17 2026

Background

Form 4 filing reports insider transactions required by SEC.

Company-level read

Ticker impact

$INCYNeutralMedium confidence
Context

President Pablo Cagnoni sold 23,218 shares for $2.8M via a 10b5‑1 plan.

Expected impact

Limited short‑term impact; possible slight downward pressure.

Evidence & confidence

Sale amount is under 1% of float and follows a pre‑arranged plan, reducing informational value.

Market effects

Sector

No broader sector impact; typical insider transaction.

Regional

None

Global

None

Counterpoint

What could challenge this read

Sale could be a routine liquidity event, not a negative signal.

Key entities

  • Insider
    Pablo Cagnoni

    President, Global Head of R&D at Incitec Pivot.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

INCY insider trading history →

Related articles

SEP 26
$MIRMHighAI 9/10

Mirum wins FDA Atebrioz approval for FOP patients 12+

Mirum Pharmaceuticals (MIRM) received FDA approval for Atebrioz to treat FOP in patients aged 12+. The drug, developed by Incyte (INCY), showed a reduction in new bone-lesion volume in a 63-patient study. U.S. availability is expected in October, with a patient support program in place. Mirum shares closed at $89.70, Incyte at $123.89 on Friday.

mugglehead.com3 min
SEP 25
$MIRMHighAI 9/10

Mirum Pharmaceuticals, Inc. and Incyte: Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced FDA approval of Atebrioz (zilurgisertib) for treating fibrodysplasia ossificans progressiva (FOP) in patients aged 12+. The once-daily oral ALK2 inhibitor showed efficacy in reducing heterotopic ossification in clinical trials. Atebrioz is expected to be available in the U.S. in October, with eligible patients paying as little as $0 per month through Mirum's patient support program.

finanznachrichten.de3 min
SEP 21
$INCYHighAI 8/10

EMA OKs Two Options for Refractory Inflammatory Conditions

The EMA's CHMP approved Povofortay (Incyte) for marketing to treat moderate to severe hidradenitis suppurativa (HS) in adults who failed anti-TNF therapy. It is the first oral option for HS, reducing pain and lesions. Cosentyx (Novartis) gained a new indication for polymyalgia rheumatica (PMR) in adults unresponsive to glucocorticoids. Both drugs showed efficacy in clinical trials.

medscape.com2 min